Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy
C Alix-Panabières, K Pantel - Cancer discovery, 2016 - AACR
Abstract “Liquid biopsy” focusing on the analysis of circulating tumor cells (CTC) and
circulating cell-free tumor DNA (ctDNA) in the blood of patients with cancer has received …
circulating cell-free tumor DNA (ctDNA) in the blood of patients with cancer has received …
Single-cell analysis of circulating tumor cells: why heterogeneity matters
Unlike bulk-cell analysis, single-cell approaches have the advantage of assessing cellular
heterogeneity that governs key aspects of tumor biology. Yet, their applications to circulating …
heterogeneity that governs key aspects of tumor biology. Yet, their applications to circulating …
Phase I study and biomarker analysis of pyrotinib, a novel irreversible Pan-ERBB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor …
F Ma, Q Li, S Chen, W Zhu, Y Fan, J Wang… - Journal of Clinical …, 2017 - ascopubs.org
Purpose This phase I study assessed the safety, tolerability, pharmacokinetics, antitumor
activity, and predictive biomarkers of pyrotinib, an irreversible pan-ErbB inhibitor, in patients …
activity, and predictive biomarkers of pyrotinib, an irreversible pan-ErbB inhibitor, in patients …
PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast …
Q Shi, J Xuhong, T Luo, J Ge, F Liu, Y Lan… - British journal of …, 2023 - nature.com
Background Neoadjuvant treatment with a dual anti-human epidermal growth factor receptor
2 (HER2) blockade with pyrotinib and trastuzumab has been shown to be effective for HER2 …
2 (HER2) blockade with pyrotinib and trastuzumab has been shown to be effective for HER2 …
Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature
F Petrelli, G Tomasello, S Barni, V Lonati… - Breast cancer research …, 2017 - Springer
Purpose HER2 gene is a member of the epidermal growth factor receptor (EGFR) family.
Across different malignancies, aberrations of HER2 gene commonly correspond to gain-of …
Across different malignancies, aberrations of HER2 gene commonly correspond to gain-of …
Effectiveness and safety of pyrotinib, and association of biomarker with progression-free survival in patients with HER2-positive metastatic breast cancer: a real-world …
Q Chen, D Ouyang, M Anwar, N Xie, S Wang… - Frontiers in …, 2020 - frontiersin.org
Background: Pyrotinib, an irreversible pan-ERBB inhibitor, has shown promising antitumour
activity, and acceptable tolerability. This research was conducted to evaluate the actual use …
activity, and acceptable tolerability. This research was conducted to evaluate the actual use …
Molecular characterization of circulating tumor cells—from bench to bedside
Y Li, S Wu, F Bai - Seminars in Cell & Developmental Biology, 2018 - Elsevier
Circulating tumor cells (CTCs) are cancer cells discovered in cancer patients' peripheral
blood that successfully escape from the primary tumor site and/or metastases, struggle to …
blood that successfully escape from the primary tumor site and/or metastases, struggle to …
[HTML][HTML] Association of PIK3CA mutation with outcomes in HER2-positive breast cancer treated with anti-HER2 therapy: A meta-analysis and bioinformatic analysis of …
H Chen, X Hu, D Wang, Y Wang, Y Yu, H Yao - Translational Oncology, 2023 - Elsevier
Background This study aimed to comprehensively explore the clinical significance of
PIK3CA mutation in human epidermal growth factor receptor 2 (HER2)-positive breast …
PIK3CA mutation in human epidermal growth factor receptor 2 (HER2)-positive breast …
Meta-analysis of HER2-enriched subtype predicting the pathological complete response within HER2-positive breast cancer in patients who received neoadjuvant …
G Shen, F Zhao, X Huo, D Ren, F Du, F Zheng… - Frontiers in …, 2021 - frontiersin.org
Background This meta-analysis aimed to better elucidate the predictive value of human
epidermal growth factor receptor 2 (HER2)-enriched subtype of pathological complete …
epidermal growth factor receptor 2 (HER2)-enriched subtype of pathological complete …
[HTML][HTML] Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer
C Gasch, T Oldopp, O Mauermann, TM Gorges… - Molecular …, 2016 - Elsevier
Modern technologies enable detection and characterization of circulating tumor cells (CTC)
in peripheral blood samples. Thus, CTC have attracted interest as markers for therapeutic …
in peripheral blood samples. Thus, CTC have attracted interest as markers for therapeutic …